CytomX Therapeutics Q3 EPS $0.04 Beats $(0.19) Estimate, Sales $26.38M Beat $14.14M Estimate
Portfolio Pulse from Benzinga Newsdesk
CytomX Therapeutics reported Q3 earnings of $0.04 per share, beating the analyst consensus estimate of $(0.19) by 121.05%. The company also reported quarterly sales of $26.38 million, beating the analyst consensus estimate of $14.14 million by 86.59%. This represents a 111.43% increase in earnings and a 55.98% increase in sales compared to the same period last year.
November 07, 2023 | 10:35 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
CytomX Therapeutics' Q3 earnings and sales significantly exceeded estimates, indicating strong financial performance.
CytomX Therapeutics reported significantly higher Q3 earnings and sales than expected, indicating strong financial performance. This is likely to increase investor confidence and could lead to a short-term increase in the company's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100